Journal SoeculationThere has been some speculation on this board that The Lancet could be the journal to watch. I would have had to agree, but with the timing of the Nasdaq listing and R&D day I Am starting to wonder if that has changed? The Lancet could publish online at anytime, so it's still a contender, but I would think if the findings are good-great it would be a headline article in the monthly print version. On the other hand, the previous egrifta and trogarzo studies were published in the NEJM. The publication of this week's NEJM would be perfect for a Thursday Nasdaq launch and give time for analyst to get familiar with the findings prior to the R&D day. Just my two cents from this morning. I to am frustrated and would usually be quick to rant, but I am taking a page from SPECO's book and trying to look on the bright side. Some guys I used to work with always said you are at the bottom and should buy in when everyone else is "puking on their shoes". To me this feels like that kind of moment... Just wish I had taken more profit last spring so I could redeploy now haha.